Author

Lorraine Cheryl Pelosof

Observed names: L. Pelosof, Lorraine C. Pelosof, Lorraine Pelosof, Lorraine Pelosof,, Pelosof, Lorraine

Institutions: National Institutes of Health, National Cancer Institute

Observed institutions: Parkland Memorial Hospital, National Institutes of Health, United States Food and Drug Administration, Center for Drug Evaluation and Research, Howard Hughes Medical Institute, Johns Hopkins University, Vanderbilt University, Washington University in St. Louis, Johns Hopkins Medicine, National Cancer Institute, Sidney Kimmel Comprehensive Cancer Center, Vanderbilt-Ingram Cancer Center, Harold C. Simmons Comprehensive Cancer Center, University of Missouri, The University of Texas Southwestern Medical Center

OpenAlex ID: A5041480735

Paraneoplastic Syndromes: An Approach to Diagnosis and Treatment

2010 · Lorraine C. Pelosof, David E. Gerber · Mayo Clinic Proceedings · 775

Four plasmepsins are active in the Plasmodium falciparum food vacuole, including a protease with an active-site histidine

2002 · Ritu Banerjee, Jun Liu, et al. · Proceedings of the National Academy of Sciences · 453

A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics

2018 · Julia A. Beaver, Lynn J. Howie, et al. · JAMA Oncology · 298

Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents

2018 · Daniel L. Suzman, Lorraine Pelosof, et al. · Liver International · 210

PDF

Whole‐exome sequencing of pancreatic neoplasms with acinar differentiation

2013 · Yuchen Jiao, Raluca Yonescu, et al. · The Journal of Pathology · 185

Proportion of Never-Smoker Non–Small Cell Lung Cancer Patients at Three Diverse Institutions

2016 · Lorraine Pelosof, Chul Ahn, et al. · JNCI Journal of the National Cancer Institute · 183

FDA Approval Summary: Nivolumab Plus Ipilimumab for the Treatment of Patients with Hepatocellular Carcinoma Previously Treated with Sorafenib

2021 · May Tun Saung, Lorraine Pelosof, et al. · The Oncologist · 108

PDF

Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public Health

2021 · Elaine Chang, Lorraine Pelosof, et al. · The Oncologist · 89

PDF

Oncologic emergencies and urgencies: A comprehensive review

2022 · Bonnie E. Gould Rothberg, Tammie E. Quest, et al. · CA A Cancer Journal for Clinicians · 81

PDF

2021 · David J. Pinato, Thomas U. Marron, et al. · European Journal of Cancer · 64

GPX3 promoter methylation predicts platinum sensitivity in colorectal cancer

2016 · Lorraine Pelosof, Sashidhar Yerram, et al. · Epigenetics · 64

PDF

A Novel Bispecific Antibody Targeting EGFR and VEGFR2 Is Effective against Triple Negative Breast Cancer via Multiple Mechanisms of Action

2021 · Nishant Mohan, Xiao Luo, et al. · Cancers · 54

PDF

Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinoma

2023 · David J. Pinato, Xiaoxue Li, et al. · JHEP Reports · 52

Transcriptome analysis of human colorectal cancer biopsies reveals extensive expression correlations among genes related to cell proliferation, lipid metabolism, immune response and collagen catabolism

2017 · Lai Xu, Rong Wang, et al. · Oncotarget · 29

Concentration-dependent Early Antivascular and Antitumor Effects of Itraconazole in Non–Small Cell Lung Cancer

2020 · David E. Gerber, William C. Putnam, et al. · Clinical Cancer Research · 27

PDF

NGS Evaluation of Colorectal Cancer Reveals Interferon Gamma Dependent Expression of Immune Checkpoint Genes and Identification of Novel IFNγ Induced Genes

2020 · Lai Xu, Lorraine Pelosof, et al. · Frontiers in Immunology · 26

PDF

Benefit-Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib

2018 · Lorraine Pelosof, Steven Lemery, et al. · The Oncologist · 24

Novel reference genes in colorectal cancer identify a distinct subset of high stage tumors and their associated histologically normal colonic tissues

2019 · Lai Xu, Helen Luo, et al. · BMC Medical Genetics · 22

PDF

CHFR silencing or microsatellite instability is associated with increased antitumor activity of docetaxel or gemcitabine in colorectal cancer

2013 · Lorraine Pelosof, Sashidhar R. Yerram, et al. · International Journal of Cancer · 21

PDF

Retrograde jejunogastric intussusception caused by a migrated gastrostomy tube

2007 · L. Pelosof, D. Ringold, et al. · Endoscopy · 16

PDF

Co-ordinate but disproportionate activation of apoptotic, regenerative and inflammatory pathways characterizes the liver response to acute amebic infection

2005 · Lorraine C. Pelosof, Paul H. Davis, et al. · Cellular Microbiology · 15

Benefit–Risk Summary of Nivolumab for the Treatment of Patients with Unresectable Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma After Prior Fluoropyrimidine- and Platinum-Based Chemotherapy

2020 · Lorraine Pelosof, May Tun Saung, et al. · The Oncologist · 11

PDF

Upregulation of TET2 and Resistance to DNA Methyltransferase (DNMT) Inhibitors in DNMT1-Deleted Cancer Cells

2024 · Angelo B. A. Laranjeira, Dat Nguyen, et al. · Diseases · 10

Rate of never smokers in non small cell lung cancer (NSCLC) patients.

2015 · Lorraine Cheryl Pelosof, Chul Ahn, et al. · Journal of Clinical Oncology · 8

Abstract A54: First-in-human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640 as monotherapy or in combination - final results of dose escalation

2015 · Andrew Brenner, Jeffrey Infante, et al. · Molecular Cancer Therapeutics · 7

Works count: 69

Citation count: 2,884

H-index: 19

I10-index: 23